WebDoctor Encyclopedia

Acute leukaemias Lymphomas

Aggressive NK-cell leukaemia (ANKL)

Aggressive NK-cell leukaemia is a very rare, fast-moving blood cancer of natural killer cells, closely linked with Epstein-Barr virus and more common in East Asia. It needs urgent asparaginase-based chemotherapy and, where possible, a donor stem cell transplant.

Medically reviewed Last reviewed October 19, 2026

What is aggressive NK-cell leukaemia?

Aggressive NK-cell leukaemia (ANKL) is a very rare and fast-growing blood cancer of natural killer (NK) cells. NK cells are white blood cells that normally help the body fight viruses and destroy abnormal cells. In ANKL, cancerous NK cells multiply rapidly and spread through the blood, bone marrow, liver and spleen.

ANKL is closely linked with the Epstein-Barr virus (EBV), the virus that causes glandular fever, and the virus is found inside the cancer cells in most cases. The disease is more common in East Asia than in Europe or North America, and it often affects younger and middle-aged adults (Ishida, 2018).

People usually become very unwell within days or weeks, with high fever, liver problems and low blood counts. For many years, the median survival was less than three months. Today, chemotherapy containing L-asparaginase followed by an allogeneic stem cell transplant offers some patients the chance of remission and possible cure.

ANKL is classified with the mature T-cell and NK-cell neoplasms. Because it is so rare, care should be given in a specialist haematology centre.

1. Key facts at a glance

Feature Details
Type of cancer Leukaemia of mature natural killer cells
How common Very rare; more frequent in East Asia
Typical age Young and middle-aged adults; median around 40 in Asian series
Sex Affects men and women
Linked virus Epstein-Barr virus in most cases
Main sites Blood, bone marrow, liver, spleen
Typical presentation High fever, enlarged liver and spleen, jaundice, low blood counts
Main treatment L-asparaginase-based chemotherapy and allogeneic stem cell transplant
Outlook Poor; survival is often measured in months without transplant

2. NK-cell cancers compared

Condition Main sites Course Outlook
Aggressive NK-cell leukaemia Blood, marrow, liver, spleen Very rapid Poor
Extranodal NK/T-cell lymphoma Nose, throat, skin, gut Rapid, but often localised at first Better if localised
Chronic lymphoproliferative disorder of NK cells Blood Slow, often without symptoms Good

3. Causes and risk factors

The exact cause of ANKL is not fully understood. Several factors are thought to play a part.

Factor Notes
Epstein-Barr virus Infects the NK cells and helps drive their growth
Geography and ancestry More common in people from East Asia and parts of Central and South America
Chronic active EBV infection A rare long-lasting EBV illness that can progress to ANKL
Gene changes in the cancer cells Changes in the JAK-STAT pathway and other signalling routes

ANKL is not inherited and not contagious. EBV infects most adults worldwide, and almost everyone with EBV never develops ANKL.

4. How does it look

In the body

Feature Description
Enlarged liver and spleen Very common; the spleen may be felt under the left ribs
Jaundice Yellowing of the skin and eyes from liver involvement
Lymph nodes Sometimes enlarged
Skin Rash or nodules are uncommon
Fluid build-up Swelling of the abdomen or around the lungs in some patients

Under the microscope

Feature Description
Blood film Abnormal large granular lymphocytes, sometimes with very atypical features
Bone marrow Infiltration by NK cells, which may be patchy
Haemophagocytosis Immune cells engulfing blood cells, a sign of an overactive immune response
Liver biopsy NK cells in the liver sinusoids

Laboratory markers

Marker Typical result
CD56 Positive
Surface CD3 Negative (distinguishes NK cells from T cells)
Cytoplasmic CD3 epsilon Positive
Cytotoxic granule proteins Positive (granzyme B, perforin, TIA-1)
EBER in situ hybridisation Positive in most cases
T-cell receptor gene studies No clonal rearrangement

The proportion of leukaemic cells in the blood and marrow can be low. In one Japanese and Korean study, 11 of 34 patients had fewer than 20% abnormal cells in both blood and marrow, yet their outcomes were similar to the others (Ishida et al., 2012).

5. Symptoms

Symptoms usually appear suddenly and get worse quickly.

Common symptoms

  • High fever that does not settle with antibiotics
  • Night sweats and weight loss
  • Tiredness and weakness
  • Pain or fullness under the ribs from an enlarged liver or spleen
  • Yellow skin and eyes
  • Easy bruising or bleeding
  • Frequent infections

Serious complications

Complication What happens
Haemophagocytic lymphohistiocytosis (HLH) An overactive immune reaction causing fever, low blood counts and organ damage
Disseminated intravascular coagulation (DIC) Abnormal blood clotting and bleeding
Liver failure Jaundice, confusion, fluid build-up
Multi-organ failure Kidneys, lungs and other organs may stop working properly

These complications explain why many patients are critically ill at diagnosis.

Understanding HLH

Haemophagocytic lymphohistiocytosis (HLH) happens when the immune system becomes dangerously overactive. Immune cells release large amounts of inflammatory chemicals and start destroying the body’s own blood cells. This causes persistent fever, an enlarged spleen, low blood counts, very high ferritin and liver damage.

In ANKL, HLH is triggered by the cancer cells and EBV. Treating HLH quickly can stabilise patients so they are well enough for chemotherapy.

When to seek medical advice

Seek urgent medical care for a high fever lasting several days, especially with yellow skin, bleeding, severe tiredness or pain under the ribs. Most fevers have simple causes, but these combinations need prompt investigation.

6. Diagnosis

Test Purpose
Full blood count and blood film Shows low counts and abnormal lymphocytes
Flow cytometry Identifies NK cells by their surface markers
Bone marrow biopsy Confirms infiltration and checks for haemophagocytosis
Liver tests and clotting tests Assess liver damage and DIC
Ferritin, triglycerides, fibrinogen Help detect HLH
Plasma EBV DNA Measures virus levels, which reflect disease burden
PET-CT Shows involved organs
Liver or spleen biopsy When marrow findings are unclear

The two main conditions to tell apart are extranodal NK/T-cell lymphoma with spread and chronic active EBV infection. Because the disease moves fast, specialists aim to make the diagnosis within days.

The role of EBV testing

Measuring EBV DNA in the blood is one of the most useful tests in ANKL. High levels at diagnosis reflect a large amount of cancer. During treatment, a falling level suggests the treatment is working, while a rising level can be an early sign of relapse. The aim of treatment is to make the virus undetectable in the blood, alongside a clear PET-CT scan (Tse et al., 2022).

7. Treatment

Treatment must begin as soon as possible and is given in a specialist haematology unit, often with intensive care support.

Supportive care

Problem Management
HLH Steroids, sometimes etoposide, and other immune-calming drugs
Bleeding and DIC Platelet and plasma transfusions
Infections Antibiotics, antifungals and antivirals
Organ failure Intensive care support

Chemotherapy

Approach Notes
L-asparaginase-based regimens The backbone of treatment, for example SMILE, DDGP or similar combinations
Avoiding anthracycline-based regimens alone NK-cell cancers resist many standard drugs, so CHOP-like regimens work poorly
Dose adjustment Often needed because of liver problems and frailty

NK-cell cancers often carry a multidrug resistance pattern, which is why anthracycline-based treatment is ineffective and asparaginase-containing regimens are preferred (Tse et al., 2022).

In a Korean study of 51 patients, L-asparaginase regimens produced responses in about 47%, compared with about 21% for other regimens. Seven patients died before chemotherapy could begin (Yoon et al., 2025).

Allogeneic stem cell transplant

An allogeneic stem cell transplant uses healthy blood stem cells from a donor. It is currently the best chance of long-term remission.

Study Finding
Japan-Korea study, 34 patients Median survival was 266 days with transplant and 36 days without (Ishida et al., 2012)
Korean study, 51 patients Responders who went on to transplant lived longer than those who did not (Yoon et al., 2025)

What happens during a stem cell transplant

Stage What happens
Finding a donor Tissue typing of siblings and searches of donor registries
Conditioning High-dose chemotherapy, sometimes with radiotherapy, to clear the marrow
Transplant day Donor stem cells are given through a drip, like a blood transfusion
Engraftment Over 2-4 weeks, the new cells start making blood
Early recovery Several weeks in hospital with protection from infection
Longer recovery Months of close follow-up as the new immune system matures

The donor’s immune cells can also attack remaining cancer cells. This graft-versus-leukaemia effect is one reason why transplant can work when chemotherapy alone does not.

Relapsed or resistant disease

Option Notes
PD-1 inhibitors Such as pembrolizumab; under study in NK-cell cancers
EBV-specific T-cell therapy Experimental
JAK inhibitors and other targeted drugs Experimental, based on gene changes
Clinical trials Strongly encouraged

Side effects

Treatment Possible side effects
L-asparaginase Allergic reactions, clotting problems, pancreatitis, liver strain, high blood sugar
Other chemotherapy Infections, bleeding, sickness, hair loss
Stem cell transplant Graft-versus-host disease, infections, organ damage

8. Outlook (prognosis)

Measure Finding
Historical median survival Less than 3 months (Ishida, 2018)
Median survival, Japan-Korea series 51 days for all 34 patients (Ishida et al., 2012)
Median overall survival, Korean series 1.6 months for 51 patients (Yoon et al., 2025)
Best outcomes Patients who respond to asparaginase chemotherapy and then have a transplant

ANKL remains one of the most serious blood cancers. Poor general health at diagnosis is common; in the Korean series, over a third of patients were too unwell to carry out most daily activities when first seen (Yoon et al., 2025). Early diagnosis and fast referral are therefore important.

9. Follow-up

Follow-up Purpose
Plasma EBV DNA Undetectable levels suggest good control
PET-CT Checks response to treatment
Bone marrow tests Confirms remission
Transplant follow-up Monitors graft-versus-host disease, infections and organ function

10. Living with aggressive NK-cell leukaemia

  • Stay close to your treatment centre during intensive treatment
  • Report fever immediately, as infections can become serious quickly
  • Follow infection precautions: hand washing, food safety and avoiding sick contacts
  • Take preventive medicines such as antivirals and antifungals as prescribed
  • Ask about palliative care early; it helps with symptoms and support alongside active treatment
  • Eat well and keep moving as much as you can; a dietitian and physiotherapist can help you stay strong
  • Keep a thermometer at home and know the temperature at which to call the hospital
  • Seek emotional support for yourself and your family from psychologists, social workers and blood cancer charities

After a transplant

Topic Advice
Medicines Take immune-suppressing drugs exactly as prescribed
Vaccinations Re-vaccination usually begins months after transplant
Sun protection Important, as skin graft-versus-host disease can be triggered by sunlight
Returning to work Often takes many months

11. Frequently asked questions

Question Answer
Is ANKL contagious? No. EBV is common, but the cancer itself cannot spread to others
Did glandular fever cause it? EBV is involved, but almost everyone with EBV never develops ANKL
Is it inherited? No; the changes that cause it develop during life and are not passed on
Why is a transplant needed? Chemotherapy alone rarely keeps ANKL away
Can I find a donor? Siblings, unrelated donors, half-matched family members or cord blood may be options
Can children get ANKL? It is very rare in children; teenagers are occasionally affected
How long is treatment? Usually a few cycles of chemotherapy, then a transplant if possible, followed by a long recovery
Are there new treatments? Immunotherapy and targeted drugs are being studied

12. Questions to ask your care team

  • How certain is the diagnosis?
  • Which chemotherapy do you recommend, and why?
  • Am I suitable for a stem cell transplant?
  • Has a donor search started?
  • Is there a clinical trial I could join?
  • How will we know whether the treatment is working?
  • What are the signs of infection or bleeding I should report straight away?
  • What support is available for my family?

Resources

  1. Ishida, F. (2018) ‘Aggressive NK-cell leukemia’, Frontiers in Pediatrics, 6, 292.
  2. Ishida, F. et al. (2012) ‘Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation’, Cancer Science, 103(6), pp. 1079-1083.
  3. Tse, E. et al. (2022) ‘How we treat NK/T-cell lymphomas’, Journal of Hematology & Oncology, 15(1), 74.
  4. Yoon, S.E. et al. (2025) ‘Aggressive natural killer cell leukemia therapy in the L-asparaginase era: why are we failing?’, Blood Research, 60(1), 55.
  5. National Cancer Institute (2026) Peripheral T-Cell Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.